Table 1.

Characteristics of AML patients and experiments

Pt No	Source	% Blasts	Disease status	FLT3 status	Cytogenetic	experiments
1	PB	90	New diagnosis	WT	46,XY	C-82
2	PB	70	New diagnosis	ITD	46,XY	C-82
3	PB	93	Relapse/refractory	WT	Complex karyotype	C-82
4	PB	74	Relapse/refractory	WT	Complex karyotype	C-82
5	PB	84	Relapse/refractory	WT	Complex karyotype	C-82
6	BM	74	Relapse/refractory	WT	Complex karyotype	C-82
7	PB	78	Relapse/refractory	WT	Complex karyotype	C-82
14	BM	52	Primary refractory	ITD + D835	47,XY, +9	C-82 + TKI
15	BM	74	New diagnosis	D835	47,XY,inv(16),+22,del(7)	C-82 + TKI
16	PB	56	Relapse/refractory	ITD	46,XY	C-82 + TKI
17	BM	83	Relapse	D835	46,XY	C-82 + TKI
18	PB	52	New diagnosis	D835	46,XY	C-82 + TKI
19	PB	72	Relapse/refractory	D835	46,XY	C-82 + TKI
20	BM	61	Relapse	WT	46,XX	C-82 + TKI
21	BM	60	New diagnosis	WT	46,XX	C-82 + TKI
22	BM	97	Relapse	WT	46,XY, t(1;3), del(7)	C-82 + TKI
23	BM	78	Relapse/refractory	ITD	46,XY	Mouse experiments

Pt No, patient number.